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Abstract
Prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasingly and is a key risk for CVD development, now recognised as the leading
cause of death globally. Dietary strategies to reduce CVD development include reduction of saturated fat intake. Milk and dairy products are
the largest contributors to dietary saturated fats in the UK and reduced consumption is often recommended as a strategy for risk reduction.
However, overall evidence from prospective cohort studies does not conﬁrm a detrimental association between dairy product consumption
and CVD risk. The present review critically evaluates the current evidence on the association between milk and dairy products and risk of
CVD, T2DM and the metabolic syndrome (collectively, cardiometabolic disease). The effects of total and individual dairy foods on
cardiometabolic risk factors and new information on the effects of the food matrix on reducing fat digestion are also reviewed. It is concluded
that a policy to lower SFA intake by reducing dairy food consumption to reduce cardiometabolic disease risk is likely to have limited or
possibly negative effects. There remain many uncertainties, including differential effects of different dairy products and those of differing fat
content. Focused and suitably designed and powered studies are needed to provide clearer evidence not only of the mechanisms involved,
but how they may be beneﬁcially inﬂuenced during milk production and processing.
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Introduction
Cardiovascular (heart and circulatory) diseases cause more than
a quarter of all deaths in the UK, or about 155 000 deaths
per year with about 41 000 of these in individuals under the age
of 75 years(1) and are the largest cause of death globally with
17·5 million deaths in 2012(2). The cost to the UK of premature
death, lost productivity, hospital treatment and prescriptions as
a result of CVD is estimated at £19 billion each year. In addition
there are now some 3·9 million individuals in the UK living with
diabetes (90 % type 2) with about 700 cases being diagnosed
every day. Projections indicate that there will be over 5 million
cases by 2025. The annual total cost (direct and indirect) of
diabetes in the UK is currently about £23·7 billion which is
projected to increase to £38·9 billion by 2035(3). The prevalence
of diabetes (mostly type 2) worldwide has almost quadrupled
since 1980 to 422 million adults, with deaths directly attributable
to diabetes being 1·5 million in 2012(2).
CVD is a group of diseases of the heart and blood
vessels and includes CHD, cerebrovascular disease, peripheral
artery disease, rheumatic heart disease, congenital heart
disease, deep vein thrombosis and pulmonary embolisms, heart
attack and stroke(2). There are a number of risk factors asso-
ciated with the development of CVD, some of which are
modiﬁable such as cigarette smoking, physical inactivity, high
blood pressure, elevated total and LDL-cholesterol, reduced
HDL-cholesterol, elevated TAG and being overweight. Out of
these risk factors, hypertension poses the greatest risk for the
development of CHD and particularly stroke, and causes
7·5 million deaths worldwide annually. However, recent data
have revealed that dietary risks now account for the greatest
loss of global disability-adjusted life years (DALY) for disease
risk factors in 2013, overtaking smoking and hypertension(4).
The lost DALY are predominantly from CVD and diabetes
(collectively along with the metabolic syndrome (MetS) now
often termed cardiometabolic disease) and this presents a key
challenge to nutrition scientists to identify effective dietary
strategies and foods that can reduce disease risk and are
acceptable and palatable to the population. A high intake of
SFA and trans-fatty acids (TFA) has been linked to an increased
risk of CVD, and this effect is thought to be mediated
predominately by increased plasma LDL-cholesterol levels(5).
The UK and WHO dietary guidelines recommend <10 % of total
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energy intake from SFA, yet the majority of countries worldwide
currently exceed this recommendation(6), with data from the
most recent UK National Diet and Nutrition Survey (NDNS)
reporting mean population SFA intakes of 12·0 % of total energy
intake(7). Milk and dairy foods (including butter) are the single
greatest contributor to dietary SFA within the UK diet con-
tributing 27 % to the adult diet and are also a source of ruminant
TFA(7). Elimination or reduction of their intake has been sug-
gested as a strategy for CVD risk reduction; however, evidence
from prospective cohort studies and randomly controlled dietary
interventions studies does not support this, showing that
consumption of milk and dairy products, except butter, is not
consistently associated with an increased risk of CVD. The present
review will examine the association between dairy products and
cardiometabolic disease events derived from long-term pro-
spective studies and the effect of milk and dairy foods on markers
of cardiometabolic disease risk measured in human randomised
controlled trials (RCT). Whilst the review will focus on adults,
some of the key issues are also relevant to children. For example,
it is notable that in the UK, children consume more SFA as
percentage of total energy than adults, and in young children
(aged 4–10 years) a greater proportion is supplied by dairy
products (about 31 %) than in adults (about 22 %)(7).
Effect of milk and dairy products on risk of CVD
The chronic effects of milk and dairy products on health would
best be examined in adequately powered RCT that use disease/
death events as the key outcomes. To date, no studies of
this design have been reported and it is unlikely that such
studies will ever be performed in the future due to the high
associated ﬁnancial costs, ethical considerations and long study
duration. Therefore, the most suitable evidence available on the
associations between milk and dairy products on chronic
diseases and survival is provided by long-term prospective
cohort studies.
Milk and total dairy product intake and CVD risk: evidence
from prospective studies
Over the past 20 years, a number of prospective cohort studies
from various parts of the world have examined the relationship
between milk and dairy product consumption and the risk of
CVD and stroke. The results from the studies either showed no
relationship(8–23) or an inverse association(24–29) between dairy
product intake and risk of CVD and stroke.
A number of recent reviews have looked speciﬁcally at the
association between milk and dairy food consumption and
CVD, some of which have conducted meta-analyses of
available cohort data (Table 1). Elwood et al.(30) reported on
meta-analyses that examined the associations between milk
and dairy products and health and survival. The Cochrane
systematic review method was used and yielded eleven papers
for CHD and four papers for stroke and diabetes. The authors
concluded that the available data indicated a possible beneﬁcial
effect of milk and dairy product consumption on risk of
CVD(30). The relative risk (RR) of stroke and IHD in subjects
with high milk and dairy product intake was 0·79 (95 % CI 0·75,
0·82) and 0·84 (95 % CI 0·76, 0·93), respectively, relative to
those with low milk and dairy product intake. This study has
been extended to examine the differential effects of milk,
cheese and butter on the incidence of vascular disease(31). The
authors reported a reduction in RR in the subjects with
the highest dairy product consumption relative to those with the
lowest intake: 0·87 (95 % CI 0·77, 0·98) for all-cause deaths, 0·92
(95 % CI 0·80, 0·99) for IHD, 0·79 (95 % CI 0·68, 0·91) for stroke
and 0·85 (95 % CI 0·75, 0·96) for incident diabetes(31). In a meta-
analysis of seventeen prospective studies Soedamah-Muthu
et al.(32) found a weak and marginally signiﬁcant inverse
association between milk intake and total CVD, but no sig-
niﬁcant association was seen with risk of stroke or CHD
although in other meta-analyses signiﬁcant inverse relationships
were seen for stroke(33) and CVD/stroke/CHD(34). The study of
Qin et al.(34) which included a total of twenty-two prospective
cohort studies reported RR 0·88 (nine studies; 95 % CI 0·81,
0·96) for CVD and RR 0·87 (twelve studies; 95 % CI 0·77, 0·99)
for stroke. No association was found between dairy product
consumption and CHD risk, which supports previous ﬁndings
from Soedamah-Muthu et al.(35).
Recent studies that were not included in all these meta-
analyses, such as The Netherlands Cohort Study consisting of
120 852 men and women with 10 years of follow-up, showed
no association between total milk and milk product intake and
stroke mortality in men and women(21). Similarly, no association
between total milk intake and IHD mortality in men was found,
whereas in women, there was a weak but signiﬁcant positive
association (RR 1·07; 95 % CI 1·01, 1·13; P for trend= 0·05).
Similarly, in the Rotterdam Study of older Dutch subjects(36),
total dairy product consumption or the intake of speciﬁc dairy
products was not related to CVD events. There was, however,
an inverse association between high-fat dairy and fatal stroke
(hazard ratio (HR) of 0·88 per 100 g/d; 95 % CI 0·79, 0·99), but
not to incident stroke(36). The ﬁndings of these studies appear to
be in broad agreement with the meta-analysis ﬁndings of
Soedamah-Muthu et al.(32).
Contrary to these ﬁndings, a study by Michaëlsson et al.(37)
reported that milk intake was signiﬁcantly associated with
markedly higher total and CVD mortality in 61 433 Swedish
women from the Swedish Mammography Cohort. This relation-
ship was also observed in a cohort of 45 339 Swedish men,
although the relationship was considerably weaker(37). However,
when these data were re-examined, an inverse association was
observed for the number of CVD deaths against milk consump-
tion(38) and, moreover, in a subset of 33 636 women also from the
Swedish Mammography Cohort, Patterson et al.(39) reported that
total dairy food intake was inversely associated with myocardial
infarction (MI) risk (multivariable adjusted HR 0·77; 95 % CI 0·63,
0·95) and milk intake was not signiﬁcantly associated with MI risk.
The inconsistent ﬁndings between milk intake and CVD mortality
observed within the same cohort require further investigation.
A recent meta-analysis by Qin et al.(34), which included a total of
twenty-two prospective cohort studies, showed an inverse asso-
ciation between dairy product consumption and overall risk of
CVD (nine studies; RR 0·88; 95 % CI 0·81, 0·96) and stroke (twelve
studies; RR 0·87; 95 % CI 0·77, 0·99). However, no association was
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Table 1. A selection of recent reviews and meta-analyses on milk and milk products or total dairy product intake and risk of CVD
Reference Dairy food Methodology Overall CVD Stroke CHD IHD
Qin et al. (2015)(34) ‘Dairy products’ as the
main exposure to
represent milk and
dairy products
Meta-analysis of 22
prospective studies
Inverse association of dairy
products and overall risk of
CVD (nine studies; RR
0·88; 95 % CI 0·81, 0·96)
Inverse association for stroke
(12 studies; RR 0·87; 95 %
CI 0·77, 0·99). RR reduced
in low-fat dairy products
No association (12
studies; RR 0·94; 95 %
CI 0·82, 1·07)
Hjerpsted & Tholstrup
(2016)(43)
Cheese Narrative review of three
correlation, five cross-
sectional, five case–
control, eight prospective
and four RCT cross-over
studies
Of eight prospective studies,
four found no association
of cheese intake and CVD,
one an increased risk, two
a decreased risk and one
no association in men but
a decreased risk in women
Hu et al. (2014)(33) Total dairy products and
subtypes
Meta-analysis of 15
prospective studies, 28
138 stroke events from
764 635 subjects
Total dairy RR 0·88 (95 % CI
0·82, 0·94); low-fat dairy
RR 0·91 (95 % CI 0·85,
0·97); fermented milk RR
0·80 (95 % CI 0·71, 0·89);
and cheese RR 0·94 (95 %
CI 0·89, 0·995) associated
with a reduced risk of
stroke
Soedamah-Muthu et al.
(2013)(32)
Milk Dose–response meta-
analysis. Seventeen
prospective studies
Modest inverse association
(four studies; RR 0·94 per
200 ml/d; 95 % CI 0·89,
0·99)
No association (six studies;
RR 0·87; 95 % CI 0·72,
1·05)
No association (six
studies; RR 1·00; 95 %
CI 0·96, 1·04)
Soedamah-Muthu et al.
(2011)(35)
Total dairy products Meta-analysis. Four
prospective cohorts
No significant association
(RR 1·02; 95 % CI 0·93,
1·11)
Soedamah-Muthu et al.
(2011)(35)
Total high-fat dairy
products
Meta-analysis. Four
prospective cohorts
No significant association
(RR 1·04; 95 % CI 0·89,
1·21)
Soedamah-Muthu et al.
(2011)(35)
Total low-fat dairy
products
Meta-analysis. Three
prospective cohorts
No significant association
(RR 0·93; 95 % CI 0·74,
1·17)
Elwood et al. (2010)(31) Milk Systematic review. Meta-
analysis of 38 cohort
studies. Five case–control
retrospective studies
Inverse association (RR
0·79; 95 % CI 0·68, 0·91)
Inverse association (RR
0·79; 95 % CI 0·68,
0·91)
Elwood et al. (2010)(31) Cheese Systematic review. Six cohort
studies used a fixed-
effects model and
weighted studies
appropriately
Inverse association (RR
0·90; 95 % CI 0·79, 1·03)
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Table 1. Continued
Reference Dairy food Methodology Overall CVD Stroke CHD IHD
Elwood et al. (2010)(31) Butter Systematic review. Five
cohort studies
Three cohort studies suggest
a reduction in vascular
disease risk (RR 0·93;
95 % CI 0·84, 1·02) while
two cross-sectional
studies suggest an
increase and another an
increase in peripheral
artery disease
Elwood et al. (2008)(30) Milk (milk, whole milk,
low-fat milk, high-fat
milk), dairy products,
dairy Ca
Meta-analysis of 15 studies
(11 for heart disease and
seven for stroke)
Inverse association (RR
0·79; 95 % CI 0·75, 0·82)
Inverse association (RR
0·83; 95 % CI 0·74,
0·91) for milk; RR 0·84
(95 % CI 0·76, 0·93) for
milk/dairy products
German et al. (2009)(158) Dairy products not
defined but include
milk, cheese and butter
Narrative review. Data from
12 cohorts involving
>280 000 subjects
Seven cohorts found no
association.
Three cohorts reported a
positive association.
One cohort reported a
positive association
between CVD and butter,
but a negative association
with cheese
German et al. (2009)(158) Cheese Narrative review. Data from
12 cohorts involving
>280 000 subjects
One cohort reported a
negative association.
Limited evidence indicates
cheese is most likely to be
associated with a reduced
risk of CVD
German et al. (2009)(158) Two cohorts used dairy
foods as a group; two
used milk intake; three
measured Ca in dairy
products; six reported
various combinations
of dairy products: milk
and cheese; milk and
butter; butter and
cheese or whole milk,
skimmed milk, high-
and low-fat dairy
products
Narrative review. Data from
12 cohorts involving
>280 000 subjects
Four found no association.
Eight reported inconsistent
associations.
No consistent evidence
that dairy food
consumption is associated
with a higher risk of CVD
RR; relative risk; RCT, randomised controlled trial.
4
J.
A
.
Lo
vegro
ve
an
d
D
.
I.
G
iven
s
http://dx.doi.org/10.1017/S0954422416000160
D
ow
nloaded from
 http:/w
w
w
.cam
bridge.org/core. The U
niversity of Reading, on 30 Sep 2016 at 11:04:22, subject to the C
am
bridge C
ore term
s of use, available at http:/w
w
w
.cam
bridge.org/core/term
s.
found between dairy product consumption and CHD risk, which
supports previous ﬁndings from Soedamah-Muthu et al.(35).
Butter
There are few studies examining the effects of individual dairy
foods such as butter on CVD risk(31). Butter is rich in milk fat and
SFA, which increase blood total and LDL-cholesterol levels and is
therefore often associated with an increased risk of CVD(40).
However, studies have shown that milk with lower fat and SFA,
and butter have similar effects on blood cholesterol levels(40).
Furthermore, a meta-analysis of data from three cohorts suggested
no effect, while two case–control studies suggested an increase in
vascular disease, and one case–control indicated an increase in
peripheral artery disease from butter intake(31). More recently
Goldbohm et al.(21) reported a slightly increased risk in all-cause
and IHD mortality for both butter and dairy fat intake (per 10 g/d;
rate ratio mortality 1·04; 95 % CI 1·01, 1·06) in women only.
However, Larsson et al.(19) in an analysis of butter intake and the
incidence of stroke found no strong association between butter
intake and stroke in men. Although there were no associations
between butter consumption and the risk of cerebral infarction or
subarachnoid haemorrhage, the risk of intracerebral bleeding was
slightly increased for men in the highest quintile of butter intake
(79g/d) compared with those in the lowest quintile (RR 1·44; 95 %
CI 1·01, 2·07), but the trend in RR with increasing butter intake was
not signiﬁcant (P=0·19)(19). In a recent cohort study, Sonestedt
et al.(41) evaluated the association between butter and cream
intake and incidence of CVD in middle-aged Swedish men and
women followed for 12 years. When the highest and lowest levels
of intake were compared, no association was found between
butter or cream intake and incident CVD (HR 0·94; 95 % CI 0·83,
1·07; P for trend=0·16; and HR 0·93; 95 % CI 0·83, 1·06; P for
trend=0·10, respectively). Overall, the evidence from prospective
studies on butter in relation to CVD risk appears conﬂicting,
although the balance of evidence suggests either no effect or a
slight detrimental impact on CVD risk; however, additional long-
term studies are required to further elucidate associations between
butter and CVD risk.
Cheese
The evidence on the effects of cheese consumption and CVD
risk is also limited(31). Elwood et al.(31) showed an estimate of
RR from cheese consumption of 0·90 (95 % CI 0·79, 1·03) in a
meta-analysis of two prospective cohort studies. The authors
found six studies in the literature examining the effects of
cheese on CVD risk, but sufﬁcient data were only available in
two of these studies. Since then a number of prospective cohort
studies have been published. For example, the Netherlands
Cohort Study reported no association between cheese intake
and IHD mortality(21). In addition, no signiﬁcant association
between full-fat cheese intake and CVD mortality was observed
in a population-based sample of Australian adults followed for
14·4 years(20). However, another recent study involving 26 445
adults from the Swedish Malmö Diet and Cancer cohort with
12 years of follow-up showed that cheese intake was signiﬁcantly
associated with CVD risk in those with the highest intake(41).
In contrast, a recent large prospective cohort study found no
association between consumption of cheese and stroke risk(42).
Patterson et al.(39) examined the association between total, as
well as speciﬁc, dairy food intakes and incidence of MI in a
prospective population-based cohort including 33 636 women
(aged 48–83 years), free from CVD, cancer, and diabetes at
baseline (1997), in the Swedish Mammography Cohort with a
follow-up of 11·6 years. Among speciﬁc dairy food products,
total cheese was inversely associated (HR 0·74; 95 % CI 0·60,
0·91) and butter used on bread, but not in cooking, was posi-
tively associated (HR 1·34; 95 % CI 1·02, 1·75) with MI risk.
Other speciﬁc dairy food products were not signiﬁcantly asso-
ciated with MI risk. No differences were observed between
consumption of speciﬁc low-fat and high-fat dairy foods,
expressed as either absolute intakes or intakes relative to the
total, and MI risk.
Recently, Hjerpsted & Tholstrup(43) published a review of the
evidence on cheese and CVD risk. They reported that four
prospective studies showed no association of cheese intake
with CVD, two showed a decreased risk and one an increased
risk. Another study showed no association in men, but a
decreased risk in women. They concluded that, when the
prospective data were considered alongside the lack of dele-
terious effects on blood cholesterol seen in the studies, overall,
cheese may not increase the risk of CVD although more work is
needed to understand the mechanisms at work.
Conclusions
The majority of prospective studies or meta-analyses examining
the relationship between milk and dairy products, except butter
consumption and risk of CVD and stroke, most, but not all
showed either no relationship or inverse associations (Table 1). A
limited number of studies examined the association between the
intake of total high-fat or total low-fat dairy products and the risk
of CHD or stroke. Therefore, additional studies of this nature are
needed, as well as studies examining the effects of individual
dairy products, particularly cheese and butter, on CVD risk.
Effect of milk and dairy products on risk of type 2 diabetes
mellitus and the metabolic syndrome
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) accounts for at least 90 % of all
diabetes cases and its prevalence has been increasing at an
alarming rate in many countries. A growing body of evidence
suggests that milk and dairy product consumption is associated
with a reduced risk of T2DM, possibly due to the beneﬁcial
effects of dairy products on obesity and the MetS, two important
risk factors for T2DM, as well as the beneﬁcial role of certain
dairy components such as protein, Ca, vitamin D, dairy fat and
speciﬁcally trans-palmitoleic acid(44,45).
Seven meta-analyses of prospective cohort studies on dairy
products and T2DM were identiﬁed (Table 2). In the meta-analysis
by Tong et al.(46) the highest dairy product consumption, com-
pared with the lowest category, showed a signiﬁcantly reduced
risk of T2DM by 14 % (pooled RR 0·86; 95 % CI 0·79, 0·92).
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Table 2. Summary of epidemiological studies on milk and dairy product intake and risk of type 2 diabetes mellitus (T2DM)
Population
characteristics
Study type and
reference
Subjects
(n) Sex
Age
(years) Other Dairy food Main outcomes
Prospective
Choi et al.
(2005)(159)
41 254 M 40–75 Healthcare professionals
without diabetes, CVD or
cancer
Total dairy product intake, LFD and HFD Consuming ≥2·9 portions/d resulted in a lower risk of T2DM compared
with ≤0·9 portions/d
Liu et al. (2006)(60) 37 183 F 55 Without diabetes, CVD or
cancer
Total dairy product intake, LFD and HFD Consuming ≥2·9 portions/d resulted in a lower risk of T2DM compared
with ≤0·85 portions/d
Elwood et al.
(2007)(61)
2375 M 45–59 Without diabetes Dairy product and/or milk intake No correlation between milk intake and T2DM
OR for metabolic syndrome lower in subjects who consumed ≥1 cup
or more of milk or other dairy products (adjusted OR for milk 0·38;
95 % CI 0·18, 0·78)
Kirii et al.
(2009)(160)
59 796 M/F 45–74 Japanese without CVD,
chronic lung disease or
chronic kidney disease
Total dairy product, Ca and vitamin D intake Ca did not reduce odds of T2DM
Intake of Ca and vitamin D reduced risk for T2DM
Dairy product intake was associated with lower odds of T2DM in
women
Fumeron et al.
(2011)(68)
3435 M/F 30–65 – Total dairy product intake (milk, cheese and other) Intake of other dairy products (not cheese) and total Ca was inversely
associated with incidence of T2DM
Margolis et al.
(2011)(161)
82 076 F 50–79 Postmenopausal women Total dairy product intake, LFD and HFD Consumption of >1·5 regular dairy product portions/d reduced the risk
of T2DM, especially among women with the highest BMI
Grantham et al.
(2012)(162)
5582 M/F 25–88 Adults ≥25 years, 209 with
and 5373 without
diabetes
Total dairy products, total milk, low-fat milk,
high-fat milk, yoghurt, cheese
Highest v. lowest total dairy product intake associated with a
significantly reduced risk of diabetes in men (OR 0·53; 95 % CI 0·29,
0·96). Similar trend for women but not significant
Sluijs et al.
(2012)(50)
16 835 M/F Mean
51–53
Adults from eight European
Union countries in EPIC-
InterAct study
Total dairy products, milk, yoghurt, cheese and
combined fermented foods
Highest v. lowest total dairy product intake not associated with T2DM
but cheese had inverse association with T2DM (HR 0·88; 95 % CI
0·76, 1·02; P for trend= 0·01)
Higher intake of all fermented foods (cheese, yoghurt and thick
fermented milk) inversely associated with T2DM (HR 0·88; 95 % CI
0·78, 0·99; P for trend= 0·02)
Soedamah-Muthu
et al. (2013)(32)
4526 M/F 56 Mostly Caucasian Total dairy product intake, LFD and HFD Inconsistent correlation with T2DM
Stuijk et al.
(2013)(163)
5953 M/F 30–60 Danish without diabetes or
CVD
LFD, HFD, milk and milk products, cheese and
FMD
No association between any total dairy products or any of the dairy
product subgroups with T2DM
Louie et al.
(2013)(69)
1802 M/F ≥49 Australian Total dairy product intake, LFD and RFD In obese subjects, high intake of regular-fat dairy foods associated with
reduced risk of T2DM; OR 0·37 (95 % CI 0·16, 0·88), not after
adjustment for additional confounders.
No association between total dairy product consumption and risk of
T2DM
Zong et al.
(2014)(164)
2091 M/F 50–70 Chinese, 6 years follow-up Total dairy products including mainly milk,
yoghurt, ice cream and milk powder
Compared with non-consumers, the RR of T2DM in those having
0·5–1 serving/d and >1 serving/d were 0·70 (95 % CI 0·55, 0·88)
and 0·65 (95 % CI 0·49, 0·85), respectively, after multivariate
adjustment
Diaz-Lopez et al.
(2016)(51)
3454 M/F 55–80 Spanish Mediterranean, 4·1
years median follow-up
Total low-fat, whole-fat, and subgroups: milk,
yoghurt, cheeses, fermented dairy products,
concentrated full fat, and processed dairy
products
Total dairy products inversely associated with T2DM risk: RR 0·68
(95 % CI 0·47, 0·98), mainly attributed to low-fat dairy; RR 0·65
(95 % CI 0·45, 0·94) for low-fat dairy products and 0·67 (95 % CI
0·46, 0·95) for low-fat milk
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Table 2. Continued
Population
characteristics
Study type and
reference
Subjects
(n) Sex
Age
(years) Other Dairy food Main outcomes
Total yoghurt consumption was associated with a lower T2DM risk
(HR 0·60; 95 % CI 0·42, 0·86; P for trend=0·002)
Meta-analyses
Pittas et al.
(2007)(165)
– – – 18 Cross-sectional studies,
eight prospective but not
all used for dairy foods
Total dairy product, Ca and vitamin D intake High Ca doses (661–1200 mg/d) and vitamin D reduced odds of T2DM
compared with low doses (219–600 mg/d)
Consumption of three to five dairy food portions/d reduced odds of
T2DM compared with 1·5 dairy portions/d
Elwood et al.
(2008)(30)
– – – Four prospective studies,
120 263 subjects, 4851
cases
Total dairy product intake Reduced risk of T2DM in individuals with the highest compared with
the lowest dairy product intake (RR 0·92; 95 % CI 0·86, 0·97)
Tong et al.
(2011)(46)
– – – Seven prospective studies,
328 029 subjects, 13 078
cases
Total dairy product intake, LFD and HFD
consumption
Dairy product consumption reduced risk of T2DM
The effect was higher with LFD (RR 0·82; 95 % CI 0·74, 0·90)
Aune et al.
(2013)(47)
– – – 17 Prospective studies,
526 482 subjects, 30 999
cases
Total dairy product intake, HFD, LFD, milk,
cheese, yoghurt and other dairy foods
Significant inverse association between total dairy product intake (RR
0·93; CI 0·87, 0·99) with ≥400 g/d, LFD (RR 0·91; CI 0·86, 0·96) with
≥200 g/d and cheese (RR 0·92; CI 0·86, 0·99) with ≥50 g/d, and RR
of T2DM
Gao et al.
(2013)(166)
– – – 13 Studies, 457 893
subjects, 27 095 cases
Total dairy product intake, HFD, LFD, milk,
cheese, yoghurt and other dairy foods
Inverse association between T2DM and total dairy products (RR 0·95;
95 % CI 0·92, 0·98) per 200 g/d, LFD (RR 0·88; 95 % CI 0·84, 0·93) per
200 g/d, cheese (RR 0·80; 95 % CI 0·69, 0·93) per 30 g/d and yoghurt
(RR 0·91; 95 % CI 0·82, 1·00) per 50 g/d
Chen et al.
(2014)(48)
– – – 14 Prospective studies,
439 790 subjects, 35 863
T2DM cases
Yoghurt associated with reduced risk of T2DM (RR 0·82; 95 % CI 0·70,
0·96) per one serving/d whereas other dairy foods and consumption
of total dairy products were not appreciably associated
Gijsbers et al.
(2016)(49)
– – – 22 Prospective studies,
total of 579 832 subjects
including 43 118 T2DM
cases
Total dairy products, LFD, yoghurt and ice cream Per 200 g/d total dairy products and LFD inversely associated with
T2DM risk: RR 0·97 (95 % CI 0·95, 1·00) and RR 0·96 (95 % CI 0·92,
1·00), respectively. Total yoghurt consumption was associated with
a lower T2DM risk at 80 v. 0 g/d: RR 0·86 (95 % CI 0·83, 0·90)
M, male; LFD, low-fat dairy products; HFD, high-fat dairy products; F, female; EPIC-InterAct, European Prospective Investigation into Cancer and Nutritional Study; FMD, fermented dairy products; HR, hazard ratio; RR, relative risk.
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A signiﬁcant inverse association was also observed for T2DM
following low-fat dairy product and yoghurt consumption.
However, high-fat dairy products and whole (regular-fat) milk
were not found to be associated with T2DM. A dose–response
analysis showed a 6 % reduced risk of T2DM with each addi-
tional daily serving of total dairy products (RR 0·94; 95 % CI
0·92, 0·97). Similarly, each additional serving of low-fat dairy
products was associated with a 10 % reduction in T2DM risk (RR
0·90; 95 % CI 0·86, 0·97). In a systematic review and meta-
analysis involving ﬁve cohort studies with 184 454 participants,
the RR for T2DM was estimated to be 15 % lower in individuals
who had a high milk intake(31).
More recently, a systematic review and dose–response meta-
analysis reported that a high intake of total dairy products was
associated with a signiﬁcant decrease in risk of T2DM (RR 0·89;
95 % CI 0·82, 0·96) and this reduction in risk was 7 % less for every
400g total dairy product consumed per d(47). In addition, signiﬁcant
inverse associations were also found for low-fat dairy products (RR
0·83; 95 % CI 0·76, 0·90), low-fat or skimmed milk (RR 0·82; 95 % CI
0·82, 0·69), cheese (RR 0·91; 95 % CI 0·84, 0·98) and yoghurt (RR
0·86; 95 % CI 0·75, 0·98), but not for high-fat dairy or total milk
when high v. low consumption was compared. The dose–response
analysis also revealed that for 200g low-fat dairy products (RR 0·91;
95 % CI 0·86, 0·96), low-fat or skimmed milk (RR 0·89; 95 % CI 0·84,
0·95) or yoghurt (RR 0·78; 95 % CI 0·60, 1·02) per d the risk of
T2DM was 9, 11 and 22 % lower, respectively. The consumption of
50g of cheese (RR 0·92; 95 % CI 0·86, 0·99) per d was also asso-
ciated with an 8 % lower risk of T2DM(47). The meta-analysis of
fourteen cohort studies by Chen et al.(48) also showed that yoghurt
was associated with reduced risk of T2DM (RR 0·82, 95 % CI 0·70,
0·96 per one serving/d) whereas other dairy foods and consump-
tion of total dairy products were not appreciably associated. The
very recent meta-analysis of Gijsbers et al.(49) involved twenty-two
prospective studies with a total of 579 832 subjects including 43 118
T2DM cases. Total dairy products and low-fat dairy products were
both inversely associated with T2DM risk (RR 0·97 per 200g/d;
95 % CI 0·95, 1·00; RR 0·96 per 200g/d; 95 % CI 0·92, 1·00,
respectively). They showed a stronger and non-linear inverse
association for yoghurt intake (80 v. 0g/d RR 0·86; 95 % CI 0·83,
0·90), suggesting that yoghurt in particular may have value for
reducing the risk of T2DM.
Recent studies support the ﬁndings from these meta-analyses.
Intake of total dairy products was not found to be associated
with T2DM in a nested case–cohort study in a random sub-
cohort (n 16 154) and incident T2DM cases (n 12 403) from the
European Prospective Investigation into Cancer and Nutritional
Study (EPIC)-InterAct in the highest v. lowest quintile of con-
sumption(50). However, it was reported that cheese intake
tended to have an inverse association with T2DM (HR 0·88;
95 % CI 0·76, 1·02; P for trend= 0·01) and a higher intake of all
fermented foods (cheese, yoghurt and thick fermented milk)
was also inversely associated with T2DM (HR 0·88; 95 %
CI 0·78, 0·99; P for trend= 0·02) after adjustment when com-
paring extreme quintiles(50). Diaz-Lopez et al.(51) also showed
that total yoghurt consumption was associated with a lower
T2DM risk (HR 0·60; 95 % CI 0·42, 0·86; P for trend= 0·002).
Overall, there is a strong and relatively consistent body of
evidence suggesting that dairy products may be associated with
a reduced risk of T2DM, which is likely to occur in a dose-
dependent manner. In addition, evidence on regular-fat dairy
products suggests no association with T2DM or a beneﬁcial
impact, and the role of fermented dairy products such as cheese
and yoghurt appears to be particularly beneﬁcial.
The metabolic syndrome
The concurrent presence of certain CVD risk factors, notably insulin
resistance, abdominal obesity, hypertension, elevated fasting blood
glucose, elevated TAG and low HDL-cholesterol, is recognised as
the MetS. This cluster of disorders has been associated with a 2-fold
greater risk of CVD events over 5–10 years(52). In addition, patients
with the MetS are ﬁve times more likely to develop T2DM
compared with patients that do not(52). The prevalence of the MetS
in adults in developed countries is 22–39 % and varies depending
on deﬁnition used and ethnicity(53–55). Recommendations for
preventing and managing the MetS include reducing obesity,
increasing physical activity and dietary change(56).
The ﬁndings of selected epidemiological studies on milk and
dairy product intake in relation to the MetS are shown in
Table 3. In a systematic review of most of the observational
studies in Table 3, Crichton et al.(57) reported that dairy product
or milk intake was inversely associated with the prevalence of
the MetS in ﬁve(58–62) out of ten cross-sectional studies.
Furthermore, individuals with the MetS were more likely to
consume high-fat dairy products compared with low-fat dairy
products in one cross-sectional study of 1181 adults(58). In the
three prospective studies examined, two found inverse
associations between incidence of the MetS and dairy product
consumption in overweight(63) and normal-weight adults(64).
There were three studies that did not ﬁnd any association
between dairy product intake and MetS prevalence(65,66) or
incidence(67). The authors of the systematic review concluded
that although the majority of studies showed beneﬁcial effects
of dairy product intake on the risk of having the MetS,
methodological differences, potential biases and other limita-
tions in the studies prevented conclusions from being drawn(57).
In a French prospective study with a 9-year follow-up,
Fumeron et al.(68) reported that dairy product (expect cheese)
consumption and dietary Ca density were inversely associated
with incident MetS and T2DM and all parameters were asso-
ciated with lower diastolic blood pressure and TAG levels. More
recently, Louie et al.(69)reported that the HR of developing the
MetS was 0·41 (95 % CI 0·23, 0·71) for the highest quartile of
regular-fat dairy product intake v. the lowest dairy product
intake in 1802 Australian adults. Shin et al.(70) reported an
inverse association between total dairy product intake
(>7 times/week) and the MetS (HR 0·75; 95 % CI 0·64, 0·88),
and milk intake (>7 times/week) and the MetS (HR 0·79; 95 %
CI 0·67, 0·92) in a prospective study of 7240 Korean adults. Few
studies have investigated the effects of butter consumption on
the MetS. One study investigated the effects of butter from
mountain-grazed dairy cows on risk markers of the MetS
compared with conventional Danish butter(71). The study was
a double-blind, randomised, 12-week, parallel intervention in
thirty-eight healthy subjects. It was reported that there were no
signiﬁcant differences in blood lipids, lipoproteins, high-sensitivity
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Table 3. Summary of epidemiological studies on milk and dairy product intake and the metabolic syndrome (MetS)
Subject
characteristics
Type of study and
reference
Subjects
(n) Sex
Age
(years) Other Dairy food Main outcomes
Prospective
Lutsey et al. (2008)(63) 9514 M/F 45–64 Enrolled in the
Atherosclerosis Risk
in Communities study
Total dairy product intake Dairy product intake inversely associated with the MetS (HR 0·87; 95 % CI 0·77, 0·98).
Individual dairy foods not associated with the MetS
Fumeron et al.
(2011)(68)
3435 M/F 30–65 French without diabetes
at baseline
Total dairy product intake (milk,
cheese and other)
Intake of other dairy products (not cheese) and total Ca was inversely associated with
incidence of IRS and fasting hyperglycaemia
Louie et al. (2013)(69) 1802 M/F ≥49 Australian Total dairy product intake, LFD
and RFD
The highest quartile had a 59 % lower risk of the MetS (OR 0·41; CI 0·23, 0·71; P for
trend=0·004) compared with the lowest quartile of RFD intake
Shin et al. (2013)(70) 7240 M/F 40–69 Korean without the MetS
at baseline
Milk, cheese and yoghurt intake Total dairy product intake (>7 times/week) was inversely associated with the risk of the
MetS (HR 0·75; 95 % CI 0·64, 0·88; P for trend <0·001).
Milk intake (>7 times/week) was inversely associated with the risk of the MetS (HR 0·79;
95 % CI 0·67, 0·92; P for trend=0·002) when compared with no milk intake/week
Cross-sectional
Yoo et al. (2004)(58) 1181 M/F 19–38 25 % African American
and 75 % whites
HFD and LFD intake Adults with the MetS consumed significantly less LFD (0·52 servings/d) and more HFD
(0·95 servings/d) than those with no risk factors (0·73 servings/d) (P<0·05)
Azadbakht et al.
(2005)(59)
827 M/F 18–74 Tehranian Milk, yoghurt and cheese
intakes
Dairy product intake was inversely associated with the MetS (OR 0·82; 95 % CI 0·63,
0·99)
Liu et al. (2006)(60) 37 183 W – Without diabetes, CVD
or cancer at baseline
Total dairy product intake, HFD,
LFD, total milk intakes
Dairy product intake was inversely associated with the MetS: total dairy products(OR
0·66; 95 % CI 0·55, 0·80), HFD (OR 0·71; 95 % CI 0·58, 0·87), LFD (OR 0·78; 95 %
CI 0·64, 0·95) and total milk (OR 0·85; 95 % CI 0·71, 1·02)
Elwood et al. (2007)(61) 2375 M 45–59 Caerphilly cohort without
diabetes at baseline
Total dairy product and milk
intakes
At baseline milk intake was inversely associated with the MetS (RR 0·38; 95 % CI 0·18,
0·78).
The highest quartile (highest energy from dairy products) was inversely associated
with the MetS (OR 0·40; 95 % CI 0·20, 0·79)
Snijder et al. (2007)(65) 2064 M/W 50–75 Dutch population from
the Hoorn study
Total dairy product intake, milk,
yoghurt, cheese and dairy
dessert intakes
No association with dairy product intake and the MetS
Ruidavets et al.
(2007)(62)
912 M 45–64 French population Total dairy product (milk and
cheese) intakes
Dairy product intake was inversely associated with the MetS (OR 0·67; 95 % CI 0·47, 0·94)
Beydoun et al.
(2008)(72)
4519 M/F ≥18 US population Dairy products (milk, cheese,
yoghurt)
Yoghurt intake was inversely associated with the MetS (OR 0·40; 95 % CI 0·18, 0·89)
Shin et al. (2009)(66) 7081 M ≥30 Korean population Total dairy product intake No association between dairy product intake and the MetS
Mennen et al.
(2000)(167)
4976 M/F 30–64 French population Dairy product intake was inversely associated with the MetS in men (OR 0·63; 95 % CI
0·40, 0·99)
Hong et al. (2012)(168) 406 M/F 22–78 Korean population Total dairy product intake Dairy product intake was associated with reduced odds of having the MetS (OR 0·46;
95 % CI 0·22, 0·95; P for trend=0·025)
Kim (2013)(169) 4862 M/F ≥19 Korean with and without
the MetS
Milk, cheese and yoghurt intake The prevalence of the MetS was significantly lower in subjects with higher milk or
yoghurt consumption (P<0·0001).
Lower odds of the MetS with high milk (OR 0·71; 95 % CI 0·55, 0·93; P for
trend=0·0066) or yoghurt (OR 0·71; 95 % CI 0·48, 1·05; P for trend=0·0067)
Drehmer et al.
(2016)(170)
15 105 M/F 35–74 Brazilian civil servants
from six cities
Total dairy product, HFD, LFD
and a range of dairy foods.
Butter included
Increased total dairy product intake, especially of full-fat dairy products, associated with
reduced risk of the MetS in middle-aged and older adults.
OR for highest total dairy product intake: 0·75 (95 % CI 0·61, 0·92, P for trend=0·002).
Data suggest that fat in dairy products may explain the potential protective effect of dairy
product intake
M, male; F, female; HR, hazard ratio; LFD, low-fat dairy products; RFD, regular-fat dairy products; IRS, insulin resistance syndrome; HFD, high-fat dairy products; RR, relative risk.
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C-reactive protein, insulin, glucose or glucose tolerance between
butters. The authors suggested that the lack of effects on blood
lipids and inﬂammation may indicate that dairy products from
mountain pasture-grazing cows are not healthier than products
from high-input conventional systems. Although some studies
suggest a possible beneﬁcial effect of milk and dairy product
consumption in relation to individual components of the MetS,
there is a need for additional studies to determine the relationship
between milk and dairy product intake and risk of the MetS(71).
A study performed in an ethnic diverse US population
revealed that the OR for MetS per one additional daily serving of
yoghurt was 0·40 (95 % CI 0·18, 0·89), whereas the opposite
was found for cheese (OR 1·16; 95 % CI 1·04, 1·29) in a cohort
of 4519 men and women(72). This beneﬁcial association of
yoghurt consumption was conﬁrmed in children living in the
USA using data from the National Health and Nutrition
Examination Survey (NHANES) cohort (5124 children aged
2–18 years)(73). Frequent yoghurt consumption (once per week)
was associated with signiﬁcantly lower metabolic proﬁles,
including plasma insulin and markers of insulin resistance(73). In
the ﬁrst 6 years of follow-up of the SUN cohort it was reported
that frequent consumption of yoghurt (>7 servings/week)
compared with low consumption (two servings/week) only
showed a non-signiﬁcant inverse association with the MetS (OR
0·84; 95 % CI 0·60, 1·18). Yet in those with the highest category
of total yoghurt consumption combined with a high fruit
consumption (above the median ≥ 264·5 g/d) a signiﬁcantly
lower risk of developing the MetS was observed (OR 0·61; 95 %
CI 0·38, 0·99) compared with those in the lowest category of
total yoghurt and fruit consumption below the study median(74).
Conclusions
The majority of studies to date suggest a beneﬁcial role of dairy
product consumption in relation to risk of the MetS and T2DM.
Further research is needed in order to better understand the role
of regular-fat and speciﬁc types of dairy products (fermented
products in particular) on the incidence of T2DM and
components of the MetS. There is a need for RCT to examine
the effects and mechanisms of long-term dairy product
consumption on cardiometabolic risk factors, particularly in
at-risk populations such as those with T2DM/MetS.
Effect of milk and dairy products on markers of
cardiometabolic disease risk
The available evidence on the relationship between milk and
dairy product consumption and individual markers of disease
risk such as elevated plasma lipids, glucose and inﬂammatory
markers, insulin resistance, hypertension and increased body
weight and composition is reviewed.
Dairy products and blood lipids
Dairy fat consists of large numbers of fatty acids and other lipid
molecules that have different effects on human health. The
fat content of ‘whole’ or ‘full-fat’ milk is approximately
3·3 g fat/100 g, which consists primarily of TAG (97–98 % of
total lipids by weight). The TAG are composed of fatty acids of
differing lengths (4–24 carbon atoms) and levels of saturation.
Whole milk contains approximately 2·2 g of SFA/100 g,
0·8 g/100 g of oleic acid (18 : 1,cis-9), the main MUFA,
0·2 g/100 g of PUFA and approximately 0·1 g/100 g of ruminant-
derived TFA. The relationship between milk fat consumption
and health is complex and numerous intervention trials, using a
variety of fat sources, have investigated the impact of dietary fat
composition on the blood lipid (including on cholesterol and
TAG) concentrations in human subjects.
There is consistent evidence that consumption of dietary
SFA increases serum total and LDL-cholesterol concentrations, a
robust indicator of CHD risk(75). In addition, evidence from a
number of prospective studies suggests increased serum total
cholesterol in high dairy product compared with low dairy
product consumers(24,27). A positive association between intake
of SFA from dairy products and total cholesterol has been
shown using evidence from studies carried out throughout the
European Union(76). However, individual SFA have been shown
to have different effects on blood lipids, for example lauric
(12 : 0), myristic (14 : 0) and palmitic (16 : 0) acids are asso-
ciated with elevated serum levels of LDL-cholesterol, whereas
stearic acid (18 : 0), which is poorly absorbed, has limited
effects on LDL-cholesterol(5). Given that much of the 12 : 0, 14 :
0 and 16 : 0 in the human diet is derived from milk fat, the
consumption of milk and dairy foods would be expected to
have adverse effects on serum LDL-cholesterol concentrations.
There is, however, some doubt that LDL-cholesterol alone, or
models including LDL-cholesterol are optimal predictors of
CVD risk(77) and perhaps especially for effects of dairy foods the
potential value of assessing LDL particle size/density and
number needs further evaluation(77,78).
However, in addition to an LDL-cholesterol-raising effect,
SFA concomitantly increase anti-atherogenic HDL-cholesterol
concentrations, which suggest that the effects of most SFA on
blood lipids are atherogenically neutral when based on the total
cholesterol:HDL-cholesterol ratio(5,79,80). However, there is no
current consensus on this relationship, as despite extensive
evidence that low HDL-cholesterol is a strong marker of CVD
risk(81) it has been suggested that serum concentrations of HDL-
cholesterol may not reﬂect HDL functionality and its capacity to
reduce risk(82). This is mainly related to the evidence that whilst
blood HDL-cholesterol concentrations have been shown to be
inversely associated with CHD risk, dietary interventions that
raise HDL-cholesterol do not result in reduced CHD risk(83). It
has been proposed that an assessment of HDL-cholesterol
efﬂux capacity, a measure of the ability of HDL to remove
cholesterol from lipid-rich macrophages, may provide more
valuable information on HDL function and may be a useful
target for therapeutic intervention(83).
It is now becoming clearer that the effects of reducing dietary
SFA are best interpreted by an understanding of which
macronutrients replace them. Reduced CVD risk has been
associated with replacement of SFA with PUFA(80,84,85) and
MUFA(86) although replacement with carbohydrate is associated
with no improvement or an increase in CVD risk(80). This has
raised the question of whether replacing a proportion of SFA in
dairy fat with MUFA and/or PUFA will lead to reduced CVD
risk. The very few RCT that have examined this were reviewed
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by Livingstone et al.(87) who concluded that whilst based on
cholesterol changes, there were indications of reduced
CVD risk from consumption of milk and dairy products with
modiﬁed fatty acid composition, compared with those of
normal milk fat composition, although the evidence available
was weak and inadequate. A new RCT (RESET; ClinicalTrials.
gov NCT02089035)(88) is investigating this in depth and pre-
liminary results from a recent meta-analysis of three prospective
studies indicated that whilst dairy fat was not signiﬁcantly
associated with CVD, models which estimated the effect of
replacing 5 % of energy from dairy fat with vegetable fat
predicted a 10 % reduction in CVD risk(89). The dairy foods that
supplied the fat were not speciﬁed and data on this are needed
to more fully understand this outcome.
In contrast to the results of studies focused on fatty acids,
Kai et al.(90) reported an inverse association between intake of
low-fat dairy products with LDL-cholesterol concentration.
Similarly, a number of intervention studies, which speciﬁcally
investigated the effects of milk and other dairy fats, did not
show signiﬁcantly increased LDL-cholesterol(91–97). Further-
more, there is evidence that fermented milk products are
hypocholesterolaemic relative to non-fermented equiva-
lents(93,98). In a meta-analysis of six relatively short-term studies
it was concluded that the consumption of fermented yoghurt
products produced a 4 and 5 % decrease in total and LDL-
cholesterol(98). Biong et al.(93) observed signiﬁcantly lower LDL-
cholesterol (P= 0·03), differences of 0·15–0·26mmol/l following
the consumption of a cheese v. a butter-enriched standard diet
for 3 weeks. More recently Maki et al.(96), showed that
there was no signiﬁcant differences in fasting lipoprotein con-
centrations in sixty-two participants with prehypertension or
stage 1 hypertension after 5 weeks of consuming one serving/d
of low-fat dairy products compared with non-dairy products.
It has also been observed that high dairy product consumption
(four servings/d) did not signiﬁcantly alter blood lipid and
lipoprotein responses compared with low dairy product con-
sumption (two servings/d) in twenty-three healthy participants
over a 6-month period(97).
A recent systematic review and meta-analysis of RCT com-
pared blood lipid responses from butter and hard cheese and
showed that the cheese lowered LDL-cholesterol and to a lesser
extent HDL-cholesterol relative to butter, despite consumption
of the same amount of dairy fat(99). There are several proposed
mechanisms for the so-called matrix effect of cheese. Cheese is
a rich source of Ca and there are indications that the Ca forms
insoluble soaps with fatty acids in the gut leading to less fat
being absorbed, as indicated by increased faecal fat excretion
in some(100) but not all(101) studies. Lorenzen & Astrup(100) also
reported an increased faecal excretion of bile acids, due possibly
to Ca binding, thus reducing the entero-hepatic recycling of bile
acids resulting in a movement of plasma LDL-cholesterol into the
liver to support further bile acid synthesis. There is also evidence
that dairy products with at least a proportion of the milk fat
globule membranes (MFGM) intact will lead to less fat being
absorbed(102). A recent study compared 40g of milk fat consumed
as either whipping cream with MFGM largely intact or butter milk
with little MFGM and found that the butter milk produced sub-
stantial increases in plasma total and LDL-cholesterol whereas the
whipping cream showed no signiﬁcant changes(102). These
various food matrix effects need to be factored into the estimate
of cardiometabolic disease risk associated with individual dairy
products. This highlights the importance of understanding the
food vehicle and matrix, which requires consideration in addition
to the overall contents. So far, only a few cheese types have been
investigated and there remains uncertainty about the mechanisms
which reduce fat absorption, although Ca appears to play a major
role. It is of note that Soerensen et al.(103) showed that milk and
cheese with the same Ca content both gave signiﬁcantly smaller
LDL-cholesterol responses than butter with a low Ca content.
A recent study comparing blood lipid responses from butter
and olive oil (both at 4·5 % energy intake) is of interest(104).
Butter increased total cholesterol and LDL-cholesterol more
than olive oil (P< 0·05) and more than the run-in period
(P< 0·005 and P< 0·05, respectively) and increased
HDL-cholesterol relative to the run-in period (P< 0·05). No
differences between butter and olive oil were seen for TAG,
high-sensitivity C-reactive protein, insulin and glucose con-
centrations. This whole area needs more detailed investigation
since it also has substantial implications for long-term energy
and Ca balance. Research to date is suggestive that the matrix
affect is mediated primarily through a reduction in absorption of
dietary fat and hence SFA by mechanisms such as Ca saponi-
ﬁcation(100) or protection by MFGM(102). No direct effects on
absorption have been reported and future research should
focus on determining the effect that the food matrix has on the
magnitude of fatty acid absorption using, for example, stable
isotope tracers. This should link to more detailed studies on the
chemistry of the resulting faecal fat/fatty acids to conﬁrm or
otherwise the presence and structure of Ca soaps and/or Ca bile
acid complexes.
The consumption of dietary TFA has long been suspected of
increasing the risk of CHD(105) and a number of epidemiological
studies have reinforced this hypothesis(106–108). The current UK
population intakes of TFA are, on average, well below the
maximum of 2 % of total energy intake set by the Department of
Health(109), at approximately 0·7 % of total energy(7). Dietary
TFA originate principally from industrial partial hydrogenation
of edible oils and bacterial hydrogenation of unsaturated fatty
acids in the rumen of ruminants. Industrially derived TFA are
mainly found in snacks and fast foods whereas ruminant-
derived TFA are naturally found in milk and dairy products.
Milk and dairy products (mainly butter and cheese) contribute
approximately 27 % of total TFA intake in the UK diet(7).
However, the isomer distribution of ruminant (normally mainly
trans-vaccenic acid; trans-18 : 1n-7) and industrially (mainly
elaidic acid; trans-18 : 1n-9) produced TFA are different and
have been shown to have differential effects on the risk of
CHD(110). In addition, a recent meta-analysis of observational
studies showed that industrially produced TFA may be posi-
tively associated with CHD (RR 1·21; 95 % CI 0·97, 1·50;
P= 0·09), whereas ruminant TFA was not (RR 0·92; 95 % CI 0·76,
1·11; P= 0·36)(105). Similar differential effects of ruminant and
industrial TFA were reported in the recent meta-analysis of de
Souza et al.(111). This study also showed an inverse association
between ruminant trans-palmitoleic acid (trans-16 : 1n-7) and
T2DM (risk ratio 0·58; 95 % CI 0·46, 0·74) which is in accord
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with two earlier studies that reported inverse associations
between plasma trans-palmitoleic acid concentration and
incident T2DM(44,45). It remains unclear, however, whether
trans-palmitoleic acid has a speciﬁc metabolic function, or
whether it is simply a marker of dairy food intake. The ﬁndings
of a differential effect of industrially and ruminant-derived TFA
on CHD and the inverse association between trans-palmitoleic
acid and T2DM are interesting and additional studies in this area
are warranted to further elucidate the role of ruminant TFA in
the diet.
Taken together, the current evidence presented in this
section suggests that, with the possible exception of 16 : 0, the
SFA proﬁle of milk may not be as detrimental for CVD risk as
previously thought, based mainly on LDL-cholesterol as the sole
indicative predictor of risk. It is, however, becoming clearer that
differences exist between dairy foods in their ability to raise
blood lipids. The contrast between butter and hard cheese is the
clearest example to date.
Dairy proteins and blood lipids
Whilst most studies have examined the impact of dairy fat/fatty
acids on blood lipids, it is now evident that milk proteins can
also inﬂuence blood lipids. The rat study of Tong et al.(112)
using a high-fat diet showed that whey protein signiﬁcantly
increased HDL-cholesterol although this has not been
consistently shown in human studies(113). Some studies have
shown whey protein to have a tendency to reduce plasma
TAG(114) and total cholesterol(115) and a meta-analysis on the
effect of whey protein on blood lipids would be valuable.
A recent study(116) showed that compared with whey protein,
casein markedly reduced postprandial TAG (22 (SD 10)%
reduction in the 6 h AUC; P< 0·05). Similar effects were seen
for plasma chylomicrons (apoB-48; P< 0·05). The authors
concluded that in healthy overweight men, casein has speciﬁc
physical interactions with fat that affect postprandial TAG,
leading to the formation of fewer chylomicrons or an increase in
chylomicron clearance. It is clear that milk proteins can have
important inﬂuences of circulating lipids and more work in this
area is needed.
Effect of milk and dairy products on blood pressure and
arterial stiffness
Hypertension deﬁned as systolic blood pressure (SBP)
≥140mmHg and/or diastolic blood pressure (DBP) of
≥90mmHg, is one of the leading risk factors for stroke, CHD,
heart failure and end-stage renal disease(117). Diet is one of the
most important factors that inﬂuence blood pressure(118). The
Dietary Approaches to Stop Hypertension (DASH) trial demon-
strated that a diet of reduced total and SFA content and high in
low-fat dairy products, and rich in fruit and vegetables sig-
niﬁcantly lowered blood pressure in normotensive and hyper-
tensive individuals. In addition, the magnitude of blood pressure
reduction was of greater magnitude after the diet rich in low-fat
dairy products compared with the fruit and vegetable-rich diet,
which omitted dairy products altogether(119). The ﬁndings from
cross-sectional and prospective observational studies have shown
an inverse association between consumption of dairy products,
particularly low-fat varieties, and risk of hypertension(64,65,120–126).
The recent results from the Framingham Heart Study Offspring
Cohort (n 2636) also showed beneﬁt from low/reduced fat dairy
products(127). High intakes of total dairy products, total low-fat/fat-
free dairy products, low-fat/skimmed milk and yoghurt were
associated with lower annualised increments in SBP and a lower
overall risk of hypertension. Unlike for most other dairy products,
the inverse association with hypertension risk seen with yoghurt
was not diminished as follow-up time increased. For yoghurt,
each additional serving was associated with a 6 % reduced risk of
hypertension (HR 0·94; 95 % CI 0·90, 0·99)(127).
A recent meta-analysis by Soedamah-Muthu et al.(125), which
included nine prospective cohort studies with a total of 57 256
participants and 15 367 hypertension cases, conﬁrmed these
relationships. Speciﬁcally they reported that total dairy products
(nine studies; consumption range about 100–700 g/d), low-fat
dairy products (six studies; about 100–500 g/d) and milk (seven
studies; about 100–500 g/d) were inversely and linearly asso-
ciated with a lower risk of hypertension. Per 200 g/d the pooled
RR were 0·97 (95 % CI 0·95, 0·99) for total dairy products, 0·96
(95 % CI 0·93, 0·99) for low-fat dairy, and 0·96 (95 % CI 0·94,
0·98) for milk. High-fat dairy products (six studies), total
fermented dairy products (four studies), yoghurt (ﬁve studies)
and cheese (eight studies) were not signiﬁcantly associated with
hypertension. Soedamah-Muthu et al.(125) concluded that the
results indicate that low-fat dairy products and milk could
contribute to the prevention of hypertension, although further
conﬁrmation is needed from RCT. A few RCT have examined
the effects of dairy products on blood pressure(96,123,128).
Furthermore, a cross-over RCT by van Meijl & Mensink(123) in
thirty-ﬁve healthy overweight and obese men and women
indicated that daily consumption of low-fat dairy products
compared with carbohydrate-rich products for 8 weeks sig-
niﬁcantly reduced SBP by 2·9mmHg (P= 0·027). However,
another study(96) observed no signiﬁcant effects of consuming
low-fat dairy products, compared with low-fat non-dairy pro-
ducts, on blood pressure in sixty-two men and women with
prehypertension or stage 1 hypertension.
In addition to the impact on blood pressure, the effect of
these foods on other, more novel, markers of vascular health is
becoming increasingly relevant. Increased central arterial
stiffening is a feature of the ageing process and the con-
sequence of many diseases such as diabetes, atherosclerosis
and chronic renal failure. Arterial stiffening is also a marker for
increased CVD risk, including MI(129), heart failure(130), total
mortality(131), stroke(132) and renal disease(133). Arterial stiffness
is measured by pulse wave velocity and the augmentation
index, both of which are predictive of heart attacks and
stroke(134) and all-cause mortality(135). Pulse wave velocity
measures the speed of propagation of the pressure wave front
along the artery, whereas the augmentation index is calculated
from the blood pressure wave form and is based on the degree
of wave reﬂection. Signiﬁcant associations between dairy
product intake and arterial pulse wave velocity have been
shown in cross-sectional(136) and longitudinal(126) cohort stu-
dies. Livingstone et al.(126) presented data from the
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Caerphilly Prospective Study, based on 2512 men followed up
for a mean of 28 years and showed a signiﬁcant inverse rela-
tionship between dairy product intake and augmentation index.
The subjects in the highest quartile of dairy product intake
(mean 480 g/d), excluding butter, had a 2 % (P= 0·02) lower
augmentation index compared with subjects with the lowest
dairy product intake (mean 154 g/d), whereas across increasing
quartiles of butter intake there were signiﬁcantly higher insulin,
TAG and total cholesterol concentrations, and DBP(126). The
mechanisms by which milk and dairy products may reduce
blood pressure and arterial stiffness are unclear. However, it is
likely that bioactive peptides released during milk protein
digestion may be involved in the relationship between dairy
product consumption and blood pressure(137,138). The bioactive
peptides inhibit the action of angiotensin I-converting enzyme,
thereby reducing blood levels of angiotensin, preventing blood
vessel constriction, and modulating endothelial integrity.
A recent meta-analysis of RCT on the effect of casein-derived
lactotripeptides conﬁrmed that they do reduce SBP and
DBP(139). Ballard et al.(140) showed that consumption of 5 g of
whey-derived peptide daily for a 2-week period signiﬁcantly
improved brachial artery ﬂow-mediated dilation response.
There is also some evidence that certain peptides from milk
proteins modulate the release of vasoconstrictor endothelin-1
by endothelial cells, thus preventing an increase in blood
pressure(141). Furthermore, milk is a complex food, containing a
variety of biologically active components such as Ca, K and Mg
that may also have an impact on blood pressure and arterial
stiffness(142).
Blood glucose and insulin resistance
The epidemiological evidence described above indicates a
potential favourable effect of milk and fermented dairy food
consumption on insulin resistance and T2DM. The effects of
milk and dairy product consumption on glucose and insulin
metabolism would be more reliably evaluated in intervention
studies than in observational studies and, although such studies
are limited, dairy products are often used as part of an SFA-rich
diet. In the KANWU study, which used a relatively large sample
size (n 162) and study duration (2× 12 weeks), a diet high in
SFA (partly composed of butter fat) resulted in a signiﬁcant
reduction in insulin sensitivity relative to a cis-MUFA-rich diet,
but only in those subjects with a total fat intake of <37 % of
total energy intake(143). In contrast, in the PREMIER study, the
consumption of a Dietary Approaches to Stop Hypertension
(DASH) diet pattern, which is lower in total fat, SFA and
cholesterol and higher in fruit and vegetables and low-fat dairy
products, resulted in a 51 % improvement in insulin sensitivity
relative to the control group following 6 months of interven-
tion(144). However, just as in the KANWU study, this trial did not
speciﬁcally examine the effects of dairy products.
The few intervention studies(94,123,128,136,145–148) that have
assessed the effects of milk and dairy product consumption on
glucose and insulin concentrations to date were included in a
recent systematic review and meta-analysis by Benatar
et al.(149). This showed that there was no signiﬁcant change in
fasting blood glucose between high- and low-fat dairy diets
(overall mean change 1·32, 95 % CI 0·19, 2·45mg/dl; 0·073,
95 % CI 0·011, 0·136mmol/l). However, insulin sensitivity as
assessed by the homeostatic model assessment of insulin
resistance (HOMA-IR) was improved by dairy product con-
sumption in two small studies(128,147) with no effect in the larger
studies(94,148). The study of Frid et al.(150) looked speciﬁcally at
the effect of whey protein (28 g) on blood glucose control after
a high-carbohydrate meal in diabetic patients. The whey protein
signiﬁcantly (P< 0·022) reduced peak glucose concentration at
60min post-consumption and the AUC from 0 to 180min by
21 %. Milk is known to have an insulinotropic effect(151) and it
has been shown that this property is most probably related to
the branched-chain amino acids in the whey protein fraction
and speciﬁcally to leucine(152). The mechanisms by which whey
protein exerts its effect are unclear but one possibility is linked
to the ﬁnding that whey has been shown to result in a much
greater stimulation of glucose-dependent insulinotropic poly-
peptide (GIP) than other food proteins such as ﬁsh, gluten and
cheese(152). The GIP response is possibly a key factor in the
higher insulin response and the subsequent lowering of serum
glucose seen after whey ingestion, at least in healthy subjects.
GIP is one of the key gut hormones released after a meal
which enhance insulin secretion in addition to that stimulated
by glucose. This so-called incretin effect can contribute up to
50–70 % of the total postprandial insulin response(153).
Whilst most of the evidence relates to the insulinotropic effect
of milk, a recent study has indicated that dairy foods may also
improve insulin sensitivity. In the study of Rideout et al.(97),
twenty-three healthy subjects completed a cross-over RCT of
12 months. Participants consumed their habitual diets and were
randomly assigned to one of two treatment groups, i.e. a
high-dairy product-supplemented group instructed to consume
four servings of dairy products/d (from milk/yoghurt) and a
low-dairy product group which consisted of just habitual diet
that did not include more than two milk or yoghurt servings/d.
At the end of the study the high-dairy group had signiﬁcantly
lower plasma insulin and HOMA-IR than the low-dairy
product group.
Overall, there is evidence that consumption of milk and dairy
products improves blood glucose homeostasis, probably as the
result of an insulinotropic effect, with much less information on
insulin sensitivity. This topic is extremely important, particularly
with the relatively consistent epidemiological evidence of the
beneﬁt of milk and dairy product consumption on risk of type 2
diabetes. Further well-designed intervention studies are needed
to more fully understand the effects and the mechanisms.
Inﬂammation
Low-grade systemic inﬂammation is now regarded as an
important component in the development of chronic disorders
including atherosclerosis, the MetS, T2DM and CVD(154). There
is therefore interest in determining the inﬂuence, if any, that
dairy foods have in the development of inﬂammation. Several
cross-sectional studies(155–157) have indicated that dairy food
consumption is inversely associated with inﬂammation. One
study(157) reported that plasma C-reactive protein, IL-6 and
TNF-α concentrations were, respectively, 29, 9 and 20 % lower
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in subjects who consumed >2 servings dairy products/d
compared with those consuming ≤1 serving/d. Because of the
limitations of cross-sectional analysis, Labonté et al.(154) under-
took a systematic review of RCT that examined the relationship
between dairy product consumption and biomarkers of inﬂam-
mation. Only eight studies with overweight or obese subjects
were identiﬁed. Only one study had inﬂammatory marker proﬁle
as its primary outcome and this showed that dairy food
consumption improved pro- and anti-inﬂammatory biomarker
concentrations compared with the low-dairy control diet.
Overall, Labonté et al.(154) concluded that dairy food con-
sumption does not lead to increased inﬂammatory biomarker
concentrations in overweight or obese subjects. However,
because only a few studies have been performed and the
variations in methodology used, no clear assessments can be
made of individual dairy products. More research is needed in
this important area.
Conclusions
The data reviewed suggest that milk and certain dairy products
are associated with reductions in blood pressure that are
clinically relevant, no increase in body weight (in isoenergetic
diets) and may not be as detrimental for CVD risk as previously
thought, based mainly on LDL-cholesterol. This is because
whilst SFA intake is associated with a clinically signiﬁcant
increase in LDL-cholesterol, there is also an increase in HDL-
cholesterol which is also of importance although there is
increasing doubt as to the interpretation of blood HDL-
cholesterol. It is uncertain whether or how consumption of
milk and dairy products improves fasting blood glucose and
insulin sensitivity and further well-designed intervention studies
are needed to resolve this question. Overall, there is an urgent
need for well-designed intervention studies with clearly deﬁned
primary outcomes to elucidate the effects of milk and individual
dairy products on cardiometabolic risk factors.
Overall conclusions
CVD causes more than a quarter of all deaths in the UK and
remains the largest cause of death globally. In addition, the pre-
valence of T2DM is rapidly rising and is a key risk for CVD
development. Dietary strategies in many parts of the world to
reduce CVD risk include reduction of saturated fat intake. Milk
and dairy products are large contributors to dietary saturated fats
in many diets and reduction of intake or elimination is often
recommended as a strategy for risk reduction. In prospective
studies or meta-analyses examining the relationship between milk
and dairy product (except butter) consumption and risk of CVD,
stroke and overall cardiometabolic disease, most, but not all show
either no relationship or inverse associations. A limited number of
studies have examined the association between the intake of total
high-fat or total low-fat dairy products and the risk of CHD or
stroke, but not all studies use the same deﬁnition of high/low-fat
products which limits interpretation of outcomes.
Milk is a complex food and contains a number of key nutrients
and bioactive components, which may be mechanistically
responsible for reduction of disease risk. The present review has
evaluated the current evidence of the association between milk
and dairy products and risk of CVD, type 2 diabetes and the MetS.
The effects of total and individual dairy foods on cardiometabolic
disease risk factors have also been reviewed. The evidence sug-
gests that dairy foods are not associated with detrimental and
possibly provide a beneﬁcial effect on CVD risk, with more
consistent evidence for a negative relationship with T2DM. Effects
of dairy foods on CVD risk factors, including plasma lipids,
suggest that the predicted hypercholesterolaemic effect of their
SFA is not consistently observed with dairy foods (except butter),
most particularly with cheese. The potential value of assessing
LDL particle size/density and number, and more functional tests
of HDL-cholesterol may be relevant as predictors of CVD risk and
need to be assessed in relation to SFA, dairy products and
cardiometabolic risk. New information on the effects of the food
matrix which may restrict fat digestion and hence fatty acid
absorption will be important in this regard. More work is needed
to understand the mechanisms involved and to assess if the food
matrix can be beneﬁcially altered during cheese making or in
other dairy processing procedures. There is growing evidence
that milk consumption is associated with lower blood pressure,
with peptides released from milk proteins during digestion and Ca
being the key proposed mechanisms of action. Overall, the lack
of a detrimental effect, and some evidence for potential beneﬁt of
milk and dairy product consumption, suggests that dietary
restriction or exclusion is not likely to be the optimum approach
for cardiometabolic disease risk reduction.
Overall, the policy to reduce SFA intake by reducing dairy
food consumption to reduce CVD risk is likely to have a limited
or possibly negative effect unless what will replace it is con-
sidered together with an understanding of food-related factors.
There still remain many uncertainties, not least the differential
effects of different dairy products and those of differing fat
content, although evidence is building of particular beneﬁts
associated with fermented dairy products and milk proteins and
studies are needed to better understand their mode of action.
Focused and suitably designed and powered research studies
are needed to provide clearer evidence not only of the
mechanisms involved, but how they may be beneﬁcially inﬂu-
enced during milk production and processing. Given the rapid
rise in T2DM prevalence, effects on this should have a high
priority. Such studies often appear to be expensive, but relative
to the current and future costs associated with cardiometabolic
disease, they are likely to be good value.
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